STARTRK-2-PANC

NCT02568267 📎

Regimen

Experimental
Entrectinib 600 mg PO QD continuous
Control
single-arm / no comparator

Population

NTRK fusion-positive locally advanced/metastatic solid tumors pooled across STARTRK-2 (NCT02568267), STARTRK-1 (NCT02097810), ALKA-372-001; overall N=54 efficacy-evaluable; pancreatic subset n=3 (ultra-rare). Doebele Lancet Oncol 2020.

Key finding

Supported FDA tissue-agnostic approval of entrectinib for NTRK fusion-positive advanced solid tumors (Aug 2019). Small PDAC subset (n=3) with 2 responders mirrors the general TRK-inhibitor class activity in fusion-positive tumors. CNS penetration is a differentiator vs larotrectinib for PDAC pts with brain mets (rare in PDAC but occasional).

Source: PMID 31838007

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.98)